<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205541</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/13/7052</org_study_id>
    <secondary_id>PHRC 13-0060</secondary_id>
    <secondary_id>2014-001169-28</secondary_id>
    <nct_id>NCT02205541</nct_id>
  </id_info>
  <brief_title>Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU</brief_title>
  <acronym>ECULISHU</acronym>
  <official_title>Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to perform the first controlled randomized prospective study using ECZ
      in pediatric STEC-HUS. This is of great interest as there is still no efficient specific
      therapy in that potentially devastating disease.

      Furthermore, published data concerning the use of ECZ in STEC-HUS are controversial,
      reflecting statistical bias in retrospective or uncontrolled studies, thus emphasizing the
      need for prospective studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemolytic and uremic syndrome (HUS), characterized by thrombocytopenia, hemolytic anemia and
      acute renal failure (ARF), mainly affects children younger than 5 years old. Shiga-toxin
      (Stx) related HUS (STEC-HUS) is due to Stx secreting bacteria (mainly enterohemorrhagic
      Escherichia Coli strains). Acute phase of STEC-HUS is severe with at least 50% of affected
      children requiring dialysis, 20% presenting neurological involvement and 5% cardiac
      involvement. Mortality rates can reach 5% in pediatric series and long-term renal sequels
      have been reported in at least 30% of surviving patients. Apart from supportive care, no
      specific treatment (such as plasma exchange) has proven its efficacy in this life-threatening
      disease.

      Recently, activation of the complement alternative pathway (CAP) has been demonstrated in
      STEC-HUS patients and experimental studies have highlighted that Stx induce CAP activation on
      human endothelial cells and platelet-leucocytes complexes, in addition to its direct cell
      toxicity inducing apoptosis, both processes ending up in microvasculature thrombosis. CAP
      activation has been demonstrated as the cause of atypical HUS (aHUS) and ECZ, a monoclonal C5
      antibody, which inhibits the terminal complement complex (TCC) formation, can efficiently
      prevent evolution to end stage renal disease in aHUS patients. In 2011, Lapeyraque et al.
      reported its possible efficacy in 3 severe STEC-HUS pediatric patients. Nevertheless, in
      STEC-HUS, ECZ has only been used in uncontrolled studies, mostly during the 2011 German
      outbreak, with conflicting results. Considering the lack of therapy to prevent
      life-threatening complications and renal sequels in STEC-HUS and the logically expected
      efficacy of ECZ, controlled studies are mandatory. In recruiting centers, STEC-HUS patients
      with ARF will be proposed to enroll the trial with the exception of patients with multiorgan.
      After parental consent, patients will be randomized to receive either ECZ or a dextrose-based
      placebo in a single blinded fashion. According to the patient body weight, there will be 3 to
      5 injections at day (D) 0, D7, D14, D21 and D28. According to the length of initial hospital
      stay, patients may have the remaining injections in the day ward of the recruiting center.
      Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients. We
      designed a single blinded study because patients treated with placebo who will develop severe
      multiorgan involvement will be switched to the ECZ arm. ECZ or placebo will be administrated
      intravenously as a 30-minute injection. In patients receiving hemodialysis, ECZ injection
      will be performed after a dialysis session. Before first injection, patients will receive a
      tetravalent meningococcal vaccine and an oral antibiotic prophylaxis to be continued up to 14
      days after last injection.

      This is a single blinded, phase III, randomized, multi-center controlled versus placebo
      clinical trial of eculizumab in STEC-HUS patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the duration in days of extrarenal epuration</measure>
    <time_frame>From the inclusion date and assessed up to 13 months</time_frame>
    <description>Extrarenal epuration means peritoneal dialysis or hemodialysis, and is assessed at each visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events as a measure of Safety and tolerance of treatment injections (ECZ or placebo)</measure>
    <time_frame>At each injection (treatment visits 2, 3, 4, 5, 6 at respectively day 0, 7, 14, 21, 28) and at each follow-up visit (7, 8, 9 respectively at month 2, 7, 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions related to the treatment (ECZ or placebo)</measure>
    <time_frame>At each injection (treatment visits 2, 3, 4, 5, 6 at respectively day 0, 7, 14, 21, 28) and at each follow-up visit (7, 8, 9 respectively at month 2, 7, 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Acute Renal Failure (ARF)</measure>
    <time_frame>Inclusion Visit (1 at day -3 to -1 ), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28), follow-up period (visits 7, 8, 9 respectively at month 2, 7, 13)</time_frame>
    <description>Duration of ARF will be evaluated as follow : urine output measurement, creatinin clearance estimated with the Schwartz 2009 assay (based on creatinin plasma levels), ionogram, proteinuria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal sequels</measure>
    <time_frame>At 1, 6 and 12 months after last injection of ECZ (follow-up visits 7, 8, 9)</time_frame>
    <description>Renal sequels will be evaluated as follow : blood pressure, creatinin clearance, ionogram, proteinuria and microalbuminuria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological abnormalities</measure>
    <time_frame>Inclusion Visit (1 at day -3 to -1), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28), follow-up period (visits 7, 8, 9 respectively at month 2, 7, 13)</time_frame>
    <description>Duration (in days) of the thrombocytopenia
Duration (in days) of the hemolytic anemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters of Complement Alternative Pathway (CAP)</measure>
    <time_frame>Inclusion visit (1 at day -3 to -1), Treatment visits (3, 4, 5, 6 at day 7, 14, 21, 28), follow-up visit (7 at month 2)</time_frame>
    <description>Blood parameters of CAP will be evaluated with plasmatic dosages of the complement components C3 and CD46.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of the Terminal Complement Complex (TCC)</measure>
    <time_frame>Inclusion visit (1 at day -3 to -1), Treatment visits (3, 4, 5, 6 at day 7, 14, 21, 28), follow-up visit (7 at month 2)</time_frame>
    <description>Inhibition of the TCC will be evaluated trough the CH50 assay and plasmatic free ECZ levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of extrarenal manifestations</measure>
    <time_frame>Inclusion Visit (1 at day -3 to -1), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28)</time_frame>
    <description>Neurological involvement (seizures, coma, focal deficit)
Cardiac involvement (cardiac failure, ischemic myocarditis, conduction or rhythm troubles)
Digestive involvement (pancreatitis, hepatitis, hemorrhagic colitis, bowel perforation, rectal prolapsus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Inclusion Visit (1 at day -3 to -1), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28), follow-up period (visits 7, 8, 9 respectively at month 2, 7, 13)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hemolytic Uremic Syndrome of Childhood</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg concentrate for solution for infusion. According to the patient body weight, there will be 3 to 5 injections administered in IV infusion at D0, D7, D14, D21 and D28.
Eculizumab (ECZ) will be administrated intravenously as a 30-minute injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of a solution with 5% glucose. The administration scheme will be the same as the Eculizumab arm : there will be 3 to 5 injections at D0, D7, D14, D21 and D28.
Placebo will be administrated intravenously as a 30-minute injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.
ECZ or placebo will be administrated intravenously as a 30-minute injection</description>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soloris®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.
ECZ or placebo will be administrated intravenously as a 30-minute injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Solution with 5% glucose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patient (1 month-18 years old)

          -  Affected by STEC-HUS defined by :

          -  Thrombocytopenia (&lt;150 000/mm3)

          -  Mechanic hemolytic anemia (Hemoglobin &lt; 10g/dL, haptoglobin &lt;LLN, lactate
             dehydrogenase (LDH) &gt;upper limit of normal (ULN) and/or bilirubin &gt; ULN, presence of
             schizocytes)

          -  ARF defined by an estimated Schwartz 2009 creatinin clearance &lt;75ml/min/1,73m²

          -  With prodromal diarrhea and/or presence of an enterohemorrhagic strain of Escherichia
             Coli and/or identification of the Stx 1 or 2 genes in the stool sample or rectal swab

          -  Written consent of the 2 parents

          -  Female patients of childbearing potential must be practicing an effective, reliable
             and medically acceptable contraceptive regimen during the entire duration of the study
             and 5 months after the end of the participation.

        Exclusion Criteria:

          -  Neonatal HUS

          -  Malignancy

          -  Known HIV infection

          -  Pregnancy or lactation

          -  Identified drug exposure-related HUS

          -  Infection-related HUS

          -  Known systemic lupus erythematosus or antiphospholipid antibody positivity or syndrome

          -  Patient already enrolled in a drug trial

          -  Patient with ongoing meningococcal infection

          -  Patient affected by aHUS or family history of aHUS

          -  STEC-HUS patient with severe multiorgan involvement at diagnostic:

               -  Neurological involvement (seizures, coma, focal deficit) with signs of
                  microangiopathy on cerebral Magnetic Resonance Imaging.

               -  Cardiac involvement (cardiac failure, ischemic myocarditis, conduction or rhythm
                  troubles)

               -  Digestive involvement (severe pancreatitis defined by lipasemia&gt;500UI/L, severe
                  hepatitis defined by transaminase &gt;x10ULN and/or prothrombin time&lt;60%,
                  hemorrhagic colitis, bowel perforation, rectal prolapsus)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Garnier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toulouse University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karine Brochard</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toulouse University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnaud Garnier, MD</last_name>
    <phone>05 34 55 85 98</phone>
    <phone_ext>33</phone_ext>
    <email>garnier.a@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Kieffer</last_name>
    <email>kieffer.i@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Boudaillez, PhD</last_name>
      <phone>03 22 66 82 66</phone>
      <phone_ext>33</phone_ext>
      <email>Boudaillez.bernard@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard Boudaillez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard Champion, MD</last_name>
      <phone>02 41 35 55 72</phone>
      <phone_ext>33</phone_ext>
      <email>gechampion@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Gérard Champion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Nobili, MD</last_name>
      <phone>03 81 21 88 15</phone>
      <phone_ext>33</phone_ext>
      <email>fnobili@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>François Nobili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pellegrin Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Llanas, MD</last_name>
      <phone>05 56 79 56 79</phone>
      <phone_ext>33</phone_ext>
      <email>Brigitte.llanas@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Llanas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morvan Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc De Parscau, PU,PH</last_name>
      <phone>02 98 22 33 81</phone>
      <phone_ext>33</phone_ext>
      <email>loic.deparscau@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc De Parscau, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>60107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guylhène Bourdat-Michel, MD</last_name>
      <phone>04 76 76 58 94</phone>
      <phone_ext>33</phone_ext>
      <email>Gbourdatmichel@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Guylhène Bourdat-Michel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeanne de Flandre Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Lahoche, MD</last_name>
      <phone>03 20 44 41 83</phone>
      <phone_ext>33</phone_ext>
      <email>Annie.LAHOCHE@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Annie Lahoche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ania Bennour, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Samaille, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Novo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mother and Child Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Guigonis, MD</last_name>
      <phone>05 55 05 86 66</phone>
      <phone_ext>33</phone_ext>
      <email>v.guigonis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vincent Guigonis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women, Mother and Child Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure Sellier-Leclerc, MD</last_name>
      <phone>04 27 85 61 82</phone>
      <phone_ext>33</phone_ext>
      <email>alaure.leclerc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anne-Laure Sellier-Leclerc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Timone Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde Caillez, MD</last_name>
      <phone>04 91 38 72 64</phone>
      <phone_ext>33</phone_ext>
      <email>mathilde.cailliez@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Mathilde Caillez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Tsimaratos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Fila, MD</last_name>
      <phone>04 67 33 66 07</phone>
      <phone_ext>33</phone_ext>
      <email>m-fila@chu-montpelier.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Fila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mother and Child Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Allain Launay, MD</last_name>
      <phone>02 40 08 35 80</phone>
      <phone_ext>33</phone_ext>
      <email>emma.allainlaunay@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Emma Allain Launay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Debré Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Kwon, MD</last_name>
      <phone>01 40 03 21 42</phone>
      <phone_ext>33</phone_ext>
      <email>theresa.kwon@rdb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Theresa Kwon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georges Deschenes, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Ulinski, PhD</last_name>
      <phone>01 44 73 74 75</phone>
      <phone_ext>33</phone_ext>
      <email>timulinski@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tim Ulinski, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rémi Salomon, PhD</last_name>
      <phone>01 44 49 40 00</phone>
      <phone_ext>33</phone_ext>
      <email>salomon@necker.fr</email>
    </contact>
    <investigator>
      <last_name>Rémi Salomon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne de Bretagne University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Taque, MD</last_name>
      <phone>02 99 26 71 62</phone>
      <phone_ext>33</phone_ext>
      <email>sophie.taque@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Taque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amélie Ryckewaert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Purpan Children Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Garnier, MD</last_name>
      <phone>05 34 55 85 98</phone>
      <phone_ext>33</phone_ext>
      <email>garnier.a@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Françoise Conte Auriol</last_name>
      <email>auriol.f@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Arnaud Garnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Decramer, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine Brochard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Tellier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clocheville Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Cloarec, MD</last_name>
      <phone>02 47 47 47 54</phone>
      <phone_ext>33</phone_ext>
      <email>s.cloarec@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvie Cloarec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie Merieau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane Benoit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eculizumab</keyword>
  <keyword>Shiga-toxin</keyword>
  <keyword>hemolytic and uremic syndrome</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Azotemia</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Shiga Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

